These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22928945)

  • 1. The clinical effects of levosimendan are not attenuated by sulfonylureas.
    Kivikko M; Nieminen MS; Pollesello P; Pohjanjousi P; Colucci WS; Teerlink JR; Mebazaa A
    Scand Cardiovasc J; 2012 Dec; 46(6):330-8. PubMed ID: 22928945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of levosimendan in clinical practice.
    Silva-Cardoso J; Ferreira J; Oliveira-Soares A; Martins-de-Campos J; Fonseca C; Lousada N; Ilídio-Moreira J; Rabaçal C; Damasceno A; Amorim S; Seabra-Gomes R; Ferreira R; Abreu-Lima C;
    Rev Port Cardiol; 2009 Feb; 28(2):143-54. PubMed ID: 19438150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
    Nieminen MS; Sandell EP
    Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
    Graudins A; Najafi J; Rur-SC MP
    Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients.
    Kivikko M; Sundberg S; Karlsson MO; Pohjanjousi P; Colucci WS
    Scand Cardiovasc J; 2011 Apr; 45(2):86-90. PubMed ID: 21133820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
    Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D
    Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan and pulmonary hypertension.
    Cavusoglu Y; Beyaztas A; Birdane A; Ata N
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):478-80. PubMed ID: 20516805
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
    Cavusoglu Y; Beyaztas A; Birdane A; Ata N
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):503-7. PubMed ID: 19346968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis.
    Qiu J; Jia L; Hao Y; Huang S; Ma Y; Li X; Wang M; Mao Y
    Life Sci; 2017 Sep; 184():30-36. PubMed ID: 28689804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of levosimendan in sepsis and septic shock.
    Pinto BB; Rehberg S; Ertmer C; Westphal M
    Curr Opin Anaesthesiol; 2008 Apr; 21(2):168-77. PubMed ID: 18443483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.